2022 was the third straight year where the coronavirus pandemic had an extreme effect on the revenue of several biopharma companies. Pfizer became the first company in industry history to rack up more than 100 billion dollars in sales. We discuss how other companies fared in 2022 and what we can expect this year. 

To learn more about the topics in this episode: 
The top 20 pharma companies by 2022 revenue
Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&A
Merck & Co. inks $11B Prometheus takeover, firing starting gun on race for blockbuster bowel market
GSK coughs up $2B to buy Bellus for late-phase rival to Merck & Co.'s stuttering gefapixant
Medtronic embarks on monthslong global layoffs, with total cuts unknown
Eli Lilly adds $1.6B to its manufacturing spending plan in Indiana, breaking a company record
J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows

The Top Line is produced by senior podcast producer Teresa Carey. The stories are by all our "Fierce" journalists. Like and subscribe wherever you listen to your podcasts.

2022 was the third straight year where the coronavirus pandemic had an extreme effect on the revenue of several biopharma companies. Pfizer became the first company in industry history to rack up more than 100 billion dollars in sales. We discuss how other companies fared in 2022 and what we can expect this year. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/top-20-pharma-companies-2022-revenue">The top 20 pharma companies by 2022 revenue</a></li>
<li><a href="https://www.fiercepharma.com/pharma/big-pharmas-finally-strike-gsk-merck-acquisitions-signaling-accelerating-pace-ma">Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&amp;A</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/merck-inks-11b-prometheus-takeover-firing-starting-gun-roivant-race-blockbuster-bowel">Merck &amp; Co. inks $11B Prometheus takeover, firing starting gun on race for blockbuster bowel market</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/gsk-coughs-2b-stop-coughs-buying-bellus-late-phase-rival-mercks-stuttering-therapy">GSK coughs up $2B to buy Bellus for late-phase rival to Merck &amp; Co.'s stuttering gefapixant</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/medtronic-embarks-months-long-global-layoffs">Medtronic embarks on monthslong global layoffs, with total cuts unknown</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/eli-lilly-adds-16b-200-new-jobs-home-state-indianas-manufacturing-breaking-company">Eli Lilly adds $1.6B to its manufacturing spending plan in Indiana, breaking a company record</a></li>
<li><a href="https://www.fiercepharma.com/pharma/leaked-abstract-show-jj-legends-carvykti-reduce-progression-or-death-74-earlier-myeloma">J&amp;J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows</a></li>
</ul>
The Top Line is produced by senior podcast producer Teresa Carey. The stories are by all our "Fierce" journalists. Like and subscribe wherever you listen to your podcasts.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;